Everolimus, the only clinically approved mTOR‐class inhibitor, though not indicated for NSCLC, has shown potential in preclinical studies to overcome EGFR‐TKI resistance and enhance antitumor efficacy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.